Stem definition | Drug id | CAS RN |
---|---|---|
immunomodulators, both stimulant/suppressive and stimulant | 1429 | 99011-02-6 |
None
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.60 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 18, 1998 | EMA | ||
Feb. 27, 1997 | FDA | MEDICIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site erythema | 87.82 | 24.52 | 22 | 1667 | 4516 | 50598919 |
Erythema | 78.92 | 24.52 | 53 | 1636 | 146361 | 50457074 |
Application site reaction | 76.15 | 24.52 | 14 | 1675 | 660 | 50602775 |
Application site scab | 56.26 | 24.52 | 9 | 1680 | 183 | 50603252 |
Application site ulcer | 54.12 | 24.52 | 8 | 1681 | 94 | 50603341 |
Off label use | 50.76 | 24.52 | 70 | 1619 | 474356 | 50129079 |
Application site erosion | 49.27 | 24.52 | 8 | 1681 | 179 | 50603256 |
Influenza like illness | 43.87 | 24.52 | 26 | 1663 | 57433 | 50546002 |
Skin erosion | 43.58 | 24.52 | 11 | 1678 | 2320 | 50601115 |
Application site pain | 42.77 | 24.52 | 12 | 1677 | 3786 | 50599649 |
Dermoid cyst | 37.69 | 24.52 | 6 | 1683 | 118 | 50603317 |
Application site inflammation | 37.20 | 24.52 | 7 | 1682 | 374 | 50603061 |
Scab | 36.30 | 24.52 | 12 | 1677 | 6550 | 50596885 |
Application site oedema | 35.91 | 24.52 | 5 | 1684 | 37 | 50603398 |
Skin reaction | 33.15 | 24.52 | 13 | 1676 | 11555 | 50591880 |
Application site discharge | 29.10 | 24.52 | 5 | 1684 | 159 | 50603276 |
Cutaneous lupus erythematosus | 28.83 | 24.52 | 8 | 1681 | 2423 | 50601012 |
Application site irritation | 27.13 | 24.52 | 7 | 1682 | 1608 | 50601827 |
Application site infection | 26.54 | 24.52 | 4 | 1685 | 54 | 50603381 |
Chronic papillomatous dermatitis | 26.54 | 24.52 | 4 | 1685 | 54 | 50603381 |
Oedema | 25.33 | 24.52 | 20 | 1669 | 70161 | 50533274 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Vital capacity decreased | 121.30 | 27.21 | 21 | 1960 | 339 | 29572207 |
Scab | 98.44 | 27.21 | 27 | 1954 | 3907 | 29568639 |
Application site erythema | 94.51 | 27.21 | 23 | 1958 | 2076 | 29570470 |
Application site reaction | 85.82 | 27.21 | 16 | 1965 | 398 | 29572148 |
Forced expiratory volume decreased | 78.28 | 27.21 | 21 | 1960 | 2792 | 29569754 |
Erythema | 77.10 | 27.21 | 53 | 1928 | 75553 | 29496993 |
Application site ulcer | 70.34 | 27.21 | 9 | 1972 | 11 | 29572535 |
Pulmonary function test decreased | 70.14 | 27.21 | 21 | 1960 | 4142 | 29568404 |
Application site inflammation | 62.53 | 27.21 | 10 | 1971 | 96 | 29572450 |
Influenza like illness | 61.99 | 27.21 | 31 | 1950 | 24439 | 29548107 |
Obstructive airways disorder | 53.54 | 27.21 | 22 | 1959 | 10994 | 29561552 |
Application site scab | 51.56 | 27.21 | 8 | 1973 | 62 | 29572484 |
Erythema multiforme | 42.97 | 27.21 | 17 | 1964 | 7700 | 29564846 |
Skin reaction | 40.34 | 27.21 | 14 | 1967 | 4403 | 29568143 |
Upper respiratory tract infection | 39.70 | 27.21 | 24 | 1957 | 27325 | 29545221 |
Application site pain | 39.56 | 27.21 | 11 | 1970 | 1668 | 29570878 |
Chills | 37.73 | 27.21 | 34 | 1947 | 71266 | 29501280 |
Application site erosion | 36.07 | 27.21 | 6 | 1975 | 75 | 29572471 |
Application site oedema | 33.19 | 27.21 | 5 | 1976 | 31 | 29572515 |
Asthma | 30.36 | 27.21 | 22 | 1959 | 33827 | 29538719 |
Application site irritation | 28.79 | 27.21 | 7 | 1974 | 627 | 29571919 |
Application site exfoliation | 27.66 | 27.21 | 5 | 1976 | 104 | 29572442 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Application site erythema | 175.89 | 24.47 | 42 | 3223 | 4647 | 64490820 |
Erythema | 141.70 | 24.47 | 98 | 3167 | 186972 | 64308495 |
Application site reaction | 138.58 | 24.47 | 25 | 3240 | 690 | 64494777 |
Application site inflammation | 101.62 | 24.47 | 18 | 3247 | 446 | 64495021 |
Application site ulcer | 94.43 | 24.47 | 14 | 3251 | 106 | 64495361 |
Scab | 87.82 | 24.47 | 28 | 3237 | 8994 | 64486473 |
Application site scab | 79.52 | 24.47 | 13 | 3252 | 196 | 64495271 |
Application site erosion | 71.55 | 24.47 | 12 | 3253 | 213 | 64495254 |
Vital capacity decreased | 69.42 | 24.47 | 15 | 3250 | 1057 | 64494410 |
Skin reaction | 67.93 | 24.47 | 25 | 3240 | 12327 | 64483140 |
Influenza like illness | 67.90 | 24.47 | 41 | 3224 | 61661 | 64433806 |
Application site oedema | 67.41 | 24.47 | 10 | 3255 | 76 | 64495391 |
Off label use | 59.95 | 24.47 | 111 | 3154 | 632695 | 63862772 |
Application site irritation | 53.32 | 24.47 | 13 | 3252 | 1563 | 64493904 |
Application site pain | 53.21 | 24.47 | 16 | 3249 | 4232 | 64491235 |
Skin erosion | 50.28 | 24.47 | 15 | 3250 | 3861 | 64491606 |
Dermoid cyst | 48.67 | 24.47 | 9 | 3256 | 285 | 64495182 |
Application site exfoliation | 47.61 | 24.47 | 9 | 3256 | 322 | 64495145 |
Pulmonary function test decreased | 42.75 | 24.47 | 15 | 3250 | 6446 | 64489021 |
Oedema | 42.46 | 24.47 | 36 | 3229 | 91899 | 64403568 |
Forced expiratory volume decreased | 41.85 | 24.47 | 15 | 3250 | 6852 | 64488615 |
Erythema multiforme | 39.00 | 24.47 | 18 | 3247 | 15683 | 64479784 |
Application site swelling | 36.09 | 24.47 | 8 | 3257 | 634 | 64494833 |
Application site dermatitis | 32.79 | 24.47 | 6 | 3259 | 179 | 64495288 |
Vitiligo | 32.60 | 24.47 | 9 | 3256 | 1759 | 64493708 |
Local reaction | 32.46 | 24.47 | 7 | 3258 | 488 | 64494979 |
Application site necrosis | 30.02 | 24.47 | 4 | 3261 | 12 | 64495455 |
Application site discharge | 29.78 | 24.47 | 6 | 3259 | 300 | 64495167 |
Obstructive airways disorder | 27.01 | 24.47 | 16 | 3249 | 23169 | 64472298 |
Application site scar | 26.20 | 24.47 | 5 | 3260 | 188 | 64495279 |
Chills | 25.47 | 24.47 | 33 | 3232 | 137231 | 64358236 |
Cutaneous lupus erythematosus | 24.76 | 24.47 | 8 | 3257 | 2674 | 64492793 |
Skin plaque | 24.57 | 24.47 | 11 | 3254 | 8929 | 64486538 |
None
Source | Code | Description |
---|---|---|
ATC | D06BB10 | DERMATOLOGICALS ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE CHEMOTHERAPEUTICS FOR TOPICAL USE Antivirals |
FDA MoA | N0000000157 | Interferon Inducers |
FDA PE | N0000009267 | Increased Cytokine Activity |
FDA PE | N0000009269 | Increased Cytokine Production |
MeSH PA | D000276 | Adjuvants, Immunologic |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007369 | Interferon Inducers |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:36710 | interferon inducers |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Verruca | indication | 30285000 | |
Actinic keratosis | indication | 201101007 | DOID:8866 |
Condyloma acuminatum | indication | 240542006 | DOID:11168 |
Superficial basal cell carcinoma | indication | 403914000 | |
Neoplasm of vulva | off-label use | 126922007 | DOID:1245 |
Sunburn | contraindication | 23346002 | |
Immunosuppression | contraindication | 38013005 | |
Autoimmune disease | contraindication | 85828009 | |
Photosensitivity | contraindication | 90128006 | |
Graft-versus-host disease | contraindication | 234646005 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.12 | Basic |
pKa2 | 5.99 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
5% | ALDARA | BAUSCH | N020723 | Feb. 27, 1997 | RX | CREAM | TOPICAL | 7696159 | April 1, 2024 | TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC) |
5% | ALDARA | BAUSCH | N020723 | Feb. 27, 1997 | RX | CREAM | TOPICAL | 7696159 | April 1, 2024 | WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 10238645 | Aug. 18, 2029 | TREATMENT OF GENITAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 10238645 | Aug. 18, 2029 | TREATMENT OF PERIANAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 8598196 | Aug. 18, 2029 | TREATMENT OF GENITAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 8598196 | Aug. 18, 2029 | TREATMENT OF PERIANAL WARTS |
2.5% | ZYCLARA | BAUSCH | N022483 | July 15, 2011 | RX | CREAM | TOPICAL | 11318130 | Dec. 11, 2029 | TREATMENT OF ACTINIC KERATOSIS |
2.5% | ZYCLARA | BAUSCH | N022483 | July 15, 2011 | RX | CREAM | TOPICAL | 8222270 | Dec. 11, 2029 | TREATMENT OF ACTINIC KERATOSIS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 10238644 | Dec. 11, 2029 | TREATMENT OF ACTINIC KERATOSIS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 8236816 | Dec. 11, 2029 | TREATMENT OF ACTINIC KERATOSIS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 8299109 | Dec. 11, 2029 | TREATMENT OF ACTINIC KERATOSIS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 10918635 | April 30, 2030 | TREATMENT OF GENITAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 10918635 | April 30, 2030 | TREATMENT OF PERIANAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 11202752 | April 30, 2030 | TREATMENT OF GENITAL WARTS |
3.75% | ZYCLARA | BAUSCH | N022483 | March 25, 2010 | RX | CREAM | TOPICAL | 11202752 | April 30, 2030 | TREATMENT OF PERIANAL WARTS |
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Toll-like receptor 7 | Membrane receptor | AGONIST | EC50 | 4.97 | CHEMBL | CHEMBL | |||
Adenosine receptor A2a | GPCR | Ki | 5.53 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.83 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.89 | DRUG MATRIX | |||||
7,8-dihydro-8-oxoguanine triphosphatase | Enzyme | IC50 | 6.19 | CHEMBL |
ID | Source |
---|---|
4021044 | VUID |
N0000148508 | NUI |
D02500 | KEGG_DRUG |
4021044 | VANDF |
C0165032 | UMLSCUI |
CHEBI:36704 | CHEBI |
6T0 | PDB_CHEM_ID |
CHEMBL1282 | ChEMBL_ID |
DB00724 | DRUGBANK_ID |
D000077271 | MESH_DESCRIPTOR_UI |
57469 | PUBCHEM_CID |
5003 | IUPHAR_LIGAND_ID |
6911 | INN_ID |
P1QW714R7M | UNII |
215085 | RXNORM |
171571 | MMSL |
171678 | MMSL |
187724 | MMSL |
4872 | MMSL |
9862 | MMSL |
006479 | NDDF |
108939005 | SNOMEDCT_US |
386941002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3133 | CREAM | 37.50 mg | TOPICAL | NDA authorized generic | 27 sections |
imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0168-0432 | CREAM | 50 mg | TOPICAL | ANDA | 25 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45802-368 | CREAM | 12.50 mg | TOPICAL | ANDA | 25 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4145 | CREAM | 50 mg | TOPICAL | ANDA | 28 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51672-4174 | CREAM | 37.50 mg | TOPICAL | ANDA | 28 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 52549-4145 | CREAM | 50 mg | TOPICAL | ANDA | 27 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-6179 | CREAM | 50 mg | TOPICAL | ANDA | 25 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8818 | CREAM | 37.50 mg | TOPICAL | NDA authorized generic | 26 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8818 | CREAM | 37.50 mg | TOPICAL | NDA authorized generic | 26 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-536 | CREAM | 50 mg | TOPICAL | ANDA | 25 sections |
Imiquimod | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68682-272 | CREAM | 37.50 mg | TOPICAL | NDA | 27 sections |
IMIQUIMOD | HUMAN PRESCRIPTION DRUG LABEL | 1 | 72189-084 | CREAM | 12.50 mg | TOPICAL | ANDA | 13 sections |
IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / NIACINAMIDE 2% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1125 | GEL | 5 g | TOPICAL | unapproved drug other | 4 sections |
IMIQUIMOD 5% / LEVOCETIRIZINE DIHYDROCHLORIDE 1% / TRETINOIN 0.05% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1126 | GEL | 5 g | TOPICAL | unapproved drug other | 4 sections |
IMIQUIMOD 5% / NIACINAMIDE 4% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-1127 | GEL | 5 g | TOPICAL | unapproved drug other | 4 sections |
IMIQUIMOD 5% / SALICYLIC ACID 30% / TRETINOIN 0.1% | HUMAN PRESCRIPTION DRUG LABEL | 3 | 72934-1128 | GEL | 5 g | TOPICAL | unapproved drug other | 4 sections |
IMIQUIMOD 5% / TRETINOIN 0.025% | HUMAN PRESCRIPTION DRUG LABEL | 2 | 72934-1129 | GEL | 5 g | TOPICAL | unapproved drug other | 4 sections |
Aldara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-260 | CREAM | 50 mg | TOPICAL | NDA | 28 sections |
Aldara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-260 | CREAM | 50 mg | TOPICAL | NDA | 28 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-270 | CREAM | 37.50 mg | TOPICAL | NDA | 27 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-270 | CREAM | 37.50 mg | TOPICAL | NDA | 27 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-271 | CREAM | 37.50 mg | TOPICAL | NDA | 27 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-271 | CREAM | 37.50 mg | TOPICAL | NDA | 27 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-276 | CREAM | 2.50 mg | TOPICAL | NDA | 27 sections |
Zyclara | HUMAN PRESCRIPTION DRUG LABEL | 1 | 99207-276 | CREAM | 2.50 mg | TOPICAL | NDA | 27 sections |